Jagsonpal Pharmaceuticals shares surged 14% to ₹263.15 following the latest announcement of its strategic acquisition of Aequitas Healthcare. The stock witnessed strong buying interest throughout Tuesday's trading session, with shares trading at ₹262.50, up 13.51% from the previous close. The market response reflects investor confidence in the company's entry into the hospital pharmaceutical segment through this transformative deal. The transaction represents a structurally transformative pivot that moves Jagsonpal from a legacy retail prescription player to an omnichannel specialty healthcare business in India.
According to reports from Business Standard, Jagsonpal Pharmaceuticals Ltd has entered into a definitive Share Purchase Agreement to acquire 85% of the paid-up equity share capital of Aequitas Healthcare Private Ltd for ₹20.8 crore. The transaction is expected to be completed by July 15, 2026, and will be funded through internal accruals. The acquisition consideration is ₹20.8 crore for an 85% stake, with the remaining 15% stake retained by existing directors who will continue association with the business. The transaction is subject to the fulfilment of customary closing conditions.
As reported by Business Standard, the proposed acquisition marks Jagsonpal's strategic entry into the hospital segment and is aligned with the company's long-term vision of strengthening its presence in India's growing healthcare ecosystem. Manish Gupta, Managing Director of Jagsonpal, stated that the acquisition provides a ready platform for meaningful presence in the hospital segment, which now contributes 10% of pharma industry sales and is growing faster. The company believes Jagsonpal's portfolio of established brands will greatly benefit from Aequitas's strong institutional relationships, delivering sustainable long-term value to shareholders.
According to Business Standard, Aequitas Healthcare, incorporated on September 7, 2017, is an eight-year-old pharmaceutical company engaged primarily in the sale of pharmaceutical products to hospitals. The company reported revenue from operations of ₹53.31 crore in FY26. Jagsonpal Pharmaceuticals has demonstrated strong recent financial performance with its standalone net profit jumping 33.13% to ₹8.76 crore on a 9.63% increase in revenue from operations to ₹64.20 crore in Q4 FY26 over Q4 FY5. The acquisition provides access to hospital channels and institutional doctor networks, supporting faster relationship building compared to organic expansion.
According to market analysts, the sharp rally reflects the market's positive reaction to Jagsonpal's acquisition of an 85% stake in Aequitas Healthcare. Ravi Singh, Chief Research Officer at MasterTrust, noted that the stock has broken above its recent resistance with strong volumes, indicating improved momentum. However, after a 13% single-day surge, some short-term profit booking cannot be ruled out. Nilesh Jain, Vice President at Centrum Finverse, advised investors holding the stock to book partial profits at current levels while expecting the stock to move towards the ₹272-280 range. Both analysts emphasize that while the acquisition has potential to strengthen Jagsonpal's product portfolio and growth prospects, investors should monitor integration progress and expected synergies translation into improved financial performance over coming quarters.
